Edition:
United Kingdom

Nanobiotix completes patient inclusion for phase II/III trial of NBTXR3


Monday, 23 Oct 2017 

Oct 23 (Reuters) - NANOBIOTIX SA ::NANOBIOTIX COMPLETES PATIENT INCLUSION FOR PHASE II/III TRIAL OF NBTXR3 IN SOFT TISSUE SARCOMA.‍LAST PATIENTS ARE EXPECTED TO START TREATMENT IN TWO TO THREE WEEKS​.‍EXPECTS TO PRESENT RESULTS OF ITS PHASE II/III TRIAL IN SOFT TISSUE SARCOMA IN FIRST HALF OF 2018​. 

Company Quote

13.05
-0.11 -0.84%
23 May 2018